Fluorouracil Overdose: Clinical Manifestations and Comprehensive Management During and After Hospitalization
Ivyruth W Andreica, BSN, PharmD, Taylor Ortiz, MD, Erin Pfeifer, PharmD, BCPS, Marina Rozov, PharmD, BCPS, Anastasiya Shakurova, PharmD, Erica Tavares, PharmD, BCPS
Trace the overall management of a fluorouracil overdose from initial exposure, through hospitalization and posthospitalization, to recovery.
Pharmacist-Run Vaccination and Medication Management Service for Patients After Bone Marrow Transplant
With advances in technique and supportive care, bone marrow transplant (BMT) patients have a longer life expectancy now than when BMT was first performed more than 40 years ago. Despite much higher mortality rates than the general population, up to 80% of BMT patients who survive 5 years posttransplantation will be alive 20 years posttransplantation. However, patients who live longer can be at higher risk for complications, in part because of changes in their body’s immune system. One of these concerns is the loss of immunity that was previously achieved through vaccination. To regain immunity to vaccine-preventable diseases, including measles, mumps, hepatitis, and diphtheria, patients need to be revaccinated following BMT.
Recent statistics from the National Cancer Institute estimate that 25% of adults with acute myeloid leukemia (AML) are expected to survive for ≥3 years. Depending on other prognostic factors, such as duration of first remission, age, performance status, cytogenetics, and prior hematopoietic stem cell transplant, the overall survival of patients with relapsed/refractory disease at 5 years was
Prescribing of Low-Molecular-Weight Heparin and Warfarin in Patients with Acute Venous Thromboembolism and Active Cancer
John Bossaer, PharmD, BCPS, Emily Flores, PharmD, BCACP, Brian Odle, PharmD, Somi Rikhye, MD, MPH, David W Stewart, PharmD, BCPS
Malignancy is a significant risk factor for venous thromboembolism (VTE), conferring a 4- to 7-fold increased risk in patients with cancer
It is important that patients treated with chemotherapy be educated about what to expect from their regimen and the correct use of supportive care medications at home.
Increased Incidence of Recurrent Venous Thromboembolism in Patients with Cancer Receiving Bevacizumab
Jonathan E. Dowell, MD, Sarah M. Gressett Ussery, PharmD, BCOP, Kevin C. Kelly, PharmD, BCPS, Sachin R. Shah, PharmD, BCOP, FCCP, Tanis L. Welch, PharmD
Angiogenesis, the development of new blood vessels from preexisting vessels, is considered to be one of the central “hallmarks” in most malignancies.
Improving Patient Care and Medication Safety: Standardizing Antiemetic Agents in Chemotherapy Order Sets in a Large Healthcare System
The Multinational Association of Supportive Care in Cancer, the American Society of Clinical Oncology, and the National Comprehensive Cancer Network (NCCN) each publish antiemetic and supportive care guidelines for patients who are undergoing chemotherapy treatment.
A Retrospective Chart Review on the Toxicity of Pegylated Asparaginase in Adult Patients with Acute Lymphoblastic Leukemia
Acute lymphoblastic leukemia (ALL) is among the most common hematologic malignancies, with an annual incidence of 6020 patients in the United States, of which 2000 to 2500 cases occur in adults. Trends have shown an early peak between the ages of 4 and 5 years, with another increase after the age of 50 years.
Evaluation of G-CSF Use in a Single Institution and Development of Pocket Reference for Primary Prophylaxis of Chemotherapy-Induced Febrile Neutropenia
Chemotherapy-induced febrile neutropenia (CIFN) is a life-threatening, costly complication that may develop in patients with cancer after receiving myelosuppressive chemotherapy. In 1991, filgrastim (Neupogen) was approved for the treatment of patients with CIFN, because it stimulates the production of neutrophils, which potentially treats and prevents febrile neutropenia.
Successful Panitumumab Administration after Cetuximab-Induced Aseptic Meningitis: A Case Report and Review
Cetuximab and panitumumab, monoclonal antibodies directed against the epidermal growth factor receptor (EGFR), are an integral component in the management of patients with metastatic colorectal cancer (mCRC), specifically those with KRAS wild-type tumors.
Page 4 of 5
Results 31 - 40 of 50
Results 31 - 40 of 50